Looking at lymph nodes in kidney cancer
Characterizing the Tumor-draining Lymph Nodes and Other Immune Sites in Renal Cell Carcinoma
NA · Yale University · NCT07038733
This project will collect blood and tissue, including tumor and draining lymph nodes, from adults with known or suspected kidney cancer who are having routine procedures to see how T cells in lymph nodes interact with tumors.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Yale University (other) |
| Drugs / interventions | Radiation |
| Locations | 1 site (New Haven, Connecticut) |
| Trial ID | NCT07038733 on ClinicalTrials.gov |
What this trial studies
Adults with known or suspected renal cell carcinoma treated at Yale New Haven Hospital or Smilow Cancer Hospital will be invited to consent to collection of excess tissue and blood during routine clinical procedures or surgery. Collected specimens include tumor, adjacent non-malignant kidney, draining and regional lymph nodes, and a blood sample for immune and genetic analyses. Samples may be taken at relevant time points (for example pre-treatment, at response, or at progression) and will be analyzed for T cell phenotype, anti-tumor effector function, and T cell receptor repertoire. Data and biospecimens will be stored and used for current and future translational research aimed at biomarker discovery and identifying therapeutic targets in kidney cancer.
Who should consider this trial
Good fit: Adults with known or suspected renal cell carcinoma who are evaluated by Yale Genitourinary Oncology providers and who will undergo clinical procedures or surgery at Yale New Haven Hospital or Smilow Cancer Hospital are eligible to participate.
Not a fit: Children are excluded and patients who do not receive care or procedures at the listed Yale locations or who cannot provide consent will not be able to participate or benefit from this protocol.
Why it matters
Potential benefit: If successful, this work could identify immune biomarkers or targets that help guide more effective, personalized treatments for people with kidney cancer.
How similar studies have performed: Related tissue- and lymph node–based immune profiling has produced useful insights in other cancers, though comprehensive T cell repertoire studies specifically in RCC are less common.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Candidates for inclusion include adult patients with either a known or suspected kidney cancer referred to Yale Genitourinary Oncology providers in the Yale Urology, Medical Oncology and Radiation Oncology or Nephrology Departments. These individuals will be receiving clinical evaluation/medical treatment/surgery/procedures at Yale New Haven Hospital or the Smilow Cancer Hospital. Participant eligibility will be determined by study investigators and will be offered protocol details. Interested participants will be invited to participate by study investigators. Consent will be obtained by study investigators or other authorized study personnel. Any potential adult participants with known or suspected kidney cancers with a renal mass who are patients of non-study physicians will be invited to participate by study personal only with the approval of their treating physician. Exclusion Criteria * Participants under the age of 18. Children will not be enrolled on the study. * Participants known to be pregnant or actively breastfeeding. * Iodine allergy hypersensitivity.
Where this trial is running
New Haven, Connecticut
- Yale University — New Haven, Connecticut, United States (RECRUITING)
Study contacts
- Principal investigator: David Braun, MD — Yale University
- Study coordinator: Stephanie Ladd
- Email: stephanie.ladd@yale.edu
- Phone: 954-895-0576
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Renal Cell Carcinoma